224 related articles for article (PubMed ID: 21107711)
1. Interleukin-21 as a potential therapeutic target for systemic lupus erythematosus.
Li J; Pan HF; Cen H; Tian J; Ma Y; Tao JH; Ye DQ
Mol Biol Rep; 2011 Aug; 38(6):4077-81. PubMed ID: 21107711
[TBL] [Abstract][Full Text] [Related]
2. The association of interleukin-21 polymorphisms with interleukin-21 serum levels and risk of systemic lupus erythematosus.
Lan Y; Luo B; Wang JL; Jiang YW; Wei YS
Gene; 2014 Mar; 538(1):94-8. PubMed ID: 24434811
[TBL] [Abstract][Full Text] [Related]
3. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression.
Herber D; Brown TP; Liang S; Young DA; Collins M; Dunussi-Joannopoulos K
J Immunol; 2007 Mar; 178(6):3822-30. PubMed ID: 17339481
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of SIGIRR in systemic lupus erythematosus.
Wang C; Feng CC; Pan HF; Wang DG; Ye DQ
Rheumatol Int; 2013 Aug; 33(8):1917-21. PubMed ID: 23546688
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-17 in systemic lupus erythematosus: A comprehensive review.
Li D; Guo B; Wu H; Tan L; Chang C; Lu Q
Autoimmunity; 2015; 48(6):353-61. PubMed ID: 25894789
[TBL] [Abstract][Full Text] [Related]
6. The pathological role of B cells in systemic lupus erythematosus: From basic research to clinical.
Feng Y; Yang M; Wu H; Lu Q
Autoimmunity; 2020 Mar; 53(2):56-64. PubMed ID: 31876195
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-25 is upregulated in patients with systemic lupus erythematosus and ameliorates murine lupus by inhibiting inflammatory cytokine production.
Li Y; Wang R; Liu S; Liu J; Pan W; Li F; Li J; Meng D
Int Immunopharmacol; 2019 Sep; 74():105680. PubMed ID: 31200339
[TBL] [Abstract][Full Text] [Related]
8. Emerging role of interleukin-22 in autoimmune diseases.
Pan HF; Li XP; Zheng SG; Ye DQ
Cytokine Growth Factor Rev; 2013 Feb; 24(1):51-7. PubMed ID: 22906768
[TBL] [Abstract][Full Text] [Related]
9. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice.
Cai Z; Wong CK; Dong J; Chu M; Jiao D; Kam NW; Lam CW; Tam LS
Clin Exp Immunol; 2015 Aug; 181(2):253-66. PubMed ID: 25845911
[TBL] [Abstract][Full Text] [Related]
10. Emerging role of IL-35 in inflammatory autoimmune diseases.
Su LC; Liu XY; Huang AF; Xu WD
Autoimmun Rev; 2018 Jul; 17(7):665-673. PubMed ID: 29729445
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of IL-27 in systemic lupus erythematosus.
Pan HF; Tao JH; Ye DQ
Expert Opin Ther Targets; 2010 May; 14(5):479-84. PubMed ID: 20350048
[TBL] [Abstract][Full Text] [Related]
12. The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target.
Koga T; Ichinose K; Kawakami A; Tsokos GC
Expert Rev Clin Immunol; 2019 Jun; 15(6):629-637. PubMed ID: 30874446
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to the generation of plasma B cells.
Nakou M; Papadimitraki ED; Fanouriakis A; Bertsias GK; Choulaki C; Goulidaki N; Sidiropoulos P; Boumpas DT
Clin Exp Rheumatol; 2013; 31(2):172-9. PubMed ID: 23137515
[TBL] [Abstract][Full Text] [Related]
14. Brief Report: Interleukin-38 Exerts Antiinflammatory Functions and Is Associated With Disease Activity in Systemic Lupus Erythematosus.
Rudloff I; Godsell J; Nold-Petry CA; Harris J; Hoi A; Morand EF; Nold MF
Arthritis Rheumatol; 2015 Dec; 67(12):3219-25. PubMed ID: 26314375
[TBL] [Abstract][Full Text] [Related]
15. IL-33: a potential therapeutic target in autoimmune diseases.
Wang S; Ding L; Liu SS; Wang C; Leng RX; Chen GM; Fan YG; Pan HF; Ye DQ
J Investig Med; 2012 Dec; 60(8):1151-6. PubMed ID: 23076162
[TBL] [Abstract][Full Text] [Related]
16. Impaired TGF-β signaling in patients with active systemic lupus erythematosus is associated with an overexpression of IL-22.
Rekik R; Smiti Khanfir M; Larbi T; Zamali I; Beldi-Ferchiou A; Kammoun O; Marzouki S; Hamzaoui S; Mrad S; Barbouche MR; Houman MH; Ben Ahmed M
Cytokine; 2018 Aug; 108():182-189. PubMed ID: 29684755
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-13: A promising therapeutic target for autoimmune disease.
Mao YM; Zhao CN; Leng J; Leng RX; Ye DQ; Zheng SG; Pan HF
Cytokine Growth Factor Rev; 2019 Feb; 45():9-23. PubMed ID: 30581068
[TBL] [Abstract][Full Text] [Related]
18. Th17 cells in rheumatoid arthritis and systemic lupus erythematosus.
Pernis AB
J Intern Med; 2009 Jun; 265(6):644-52. PubMed ID: 19493058
[TBL] [Abstract][Full Text] [Related]
19. Association between Interleukin 35 Gene Single Nucleotide Polymorphisms and Systemic Lupus Erythematosus in a Chinese Han Population.
Guan SY; Liu LN; Mao YM; Zhao CN; Wu Q; Dan YL; Bellua Sam N; Pan HF
Biomolecules; 2019 Apr; 9(4):. PubMed ID: 31013577
[TBL] [Abstract][Full Text] [Related]
20. Targeting interleukin-21 in rheumatoid arthritis.
Yuan FL; Hu W; Lu WG; Li X; Li JP; Xu RS; Li CW; Chen FH; Jin C
Mol Biol Rep; 2011 Mar; 38(3):1717-21. PubMed ID: 20848219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
